- Home
- FLR vs LEGN Comparison
FLR vs LEGN Comparison
Compare FLR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLR
- LEGN
- Stock Information
- Founded
- FLR 1912
- LEGN 2014
- Country
- FLR United States
- LEGN United States
- Employees
- FLR N/A
- LEGN N/A
- Industry
- FLR Military/Government/Technical
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- FLR Industrials
- LEGN Health Care
- Exchange
- FLR Nasdaq
- LEGN Nasdaq
- Market Cap
- FLR 7.2B
- LEGN 6.3B
- IPO Year
- FLR N/A
- LEGN 2020
- Fundamental
- Price
- FLR $43.03
- LEGN $31.46
- Analyst Decision
- FLR Buy
- LEGN Strong Buy
- Analyst Count
- FLR 7
- LEGN 12
- Target Price
- FLR $50.57
- LEGN $73.36
- AVG Volume (30 Days)
- FLR 3.3M
- LEGN 1.2M
- Earning Date
- FLR 11-07-2025
- LEGN 11-11-2025
- Dividend Yield
- FLR N/A
- LEGN N/A
- EPS Growth
- FLR 970.51
- LEGN N/A
- EPS
- FLR 24.07
- LEGN N/A
- Revenue
- FLR $16,313,000,000.00
- LEGN $796,838,000.00
- Revenue This Year
- FLR $3.29
- LEGN $69.31
- Revenue Next Year
- FLR $4.33
- LEGN $52.73
- P/E Ratio
- FLR $1.78
- LEGN N/A
- Revenue Growth
- FLR 3.61
- LEGN 74.75
- 52 Week Low
- FLR $29.20
- LEGN $27.34
- 52 Week High
- FLR $60.10
- LEGN $51.77
- Technical
- Relative Strength Index (RSI)
- FLR 50.07
- LEGN 31.45
- Support Level
- FLR $42.53
- LEGN $32.02
- Resistance Level
- FLR $44.62
- LEGN $32.62
- Average True Range (ATR)
- FLR 1.54
- LEGN 1.02
- MACD
- FLR 0.21
- LEGN -0.09
- Stochastic Oscillator
- FLR 49.80
- LEGN 6.87
About FLR Fluor Corporation
Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services.It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $16.3 billion in revenue in 2024.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.